Cambridge Investment Research Advisors
SRNE

Cambridge Investment Research Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-101,326
Closed -$90K – 3302
2022
Q4 		$90K Buy
101,326
+1,273
+1% +$1.69K ﹤0.01% 2930
2022
Q3 		$157K Buy
100,053
+10,095
+11% +$22.9K ﹤0.01% 2771
2022
Q2 		$181K Buy
89,958
+2,556
+3% +$4.42K ﹤0.01% 2747
2022
Q1 		$204K Buy
87,402
+23,706
+37% +$73.9K ﹤0.01% 2856
2021
Q4 		$296K Sell
63,696
-20,648
-24% -$128K ﹤0.01% 2538
2021
Q3 		$644K Sell
84,344
-932
-1% -$7.9K ﹤0.01% 1849
2021
Q2 		$826K Sell
85,276
-2,750
-3% -$21.9K ﹤0.01% 1678
2021
Q1 		$728K Sell
88,026
-6,806
-7% -$71.9K ﹤0.01% 1642
2020
Q4 		$647K Buy
94,832
+36,326
+62% +$292K ﹤0.01% 1597
2020
Q3 		$652K Buy
58,506
+15,491
+36% +$142K ﹤0.01% 1436
2020
Q2 		$270K Buy
+43,015
New +$165K ﹤0.01% 1961

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Cambridge Investment Research Advisors's SRNE Position: Q1 2023 in Review

Cambridge Investment Research Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 101,326 shares — an estimated $90K sold.

Cambridge Investment Research Advisors first reported a position in SRNE in Q2 2020 and held it in 11 quarters. The position peaked at $826K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Cambridge Investment Research Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 101,326 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $90K.
  • Cambridge Investment Research Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
  • Cambridge Investment Research Advisors's Sorrento Therapeutics, Inc. position peaked at $826K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2023, filed 11 May 2023.